Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for the treatment of pain, substance abuse and dependency, schizophrenia, Alzheimer’s disease and sleep disorders.
A patent from Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. describes new multi-membered macrocyclic compounds acting as GTPase KRAS G12C, G12V and/or G13D mutant inhibitors.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have defined cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of chronic kidney disease, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome as well as kidney and myocardial fibrosis.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified TNF-α inhibitors reported to be useful for the treatment of autoimmune diseases.
Researchers at Changzhou Hengbang Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described polypeptides acting as C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of cancer, infections, cardiovascular disorders, endocrine disorders and immunological disorders.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described compounds acting as gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD, NAFLD), diabetes and obesity.
Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged pentacyclic derivatives reported to be useful for the treatment of autoimmune disease.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized new mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of urticaria.
